ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,259.59
0.14%
Dow Jones
39,112.16
-0.76%
Gold vs US Dollar
2,309.615
-0.48%
Brent Oil
84.935
0.89%
Bitcoin
61,291.04
-0.84%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Hoth Therapeutics Inc (HOTH)

  7. Hoth Therapeutics Inc (HOTH) News

Hoth Therapeutics (HOTH)

Hoth Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:HOTH
DateTimeSourceHeadlineSymbolCompany
18/06/202411:15Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:HOTHHoth Therapeutics Inc
18/06/202411:10Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:HOTHHoth Therapeutics Inc
18/06/202411:07Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:HOTHHoth Therapeutics Inc
17/06/202421:41Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:HOTHHoth Therapeutics Inc
10/06/202413:11PR Newswire (US)Hoth Therapeutics Announces Joint Development Agreement with Wise Systems International SRL to Utilize Artificial Intelligence for Drug DiscoveryNASDAQ:HOTHHoth Therapeutics Inc
14/05/202421:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:HOTHHoth Therapeutics Inc
01/05/202413:00PR Newswire (US)Hoth Therapeutics to Attend EF Hutton Annual Global Conference, May 15, 2024NASDAQ:HOTHHoth Therapeutics Inc
27/03/202418:00PR Newswire (US)Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross ProceedsNASDAQ:HOTHHoth Therapeutics Inc
27/03/202412:27PR Newswire (US)Hoth Therapeutics' Wholly Owned Subsidiary Merveille.ai, Advances AI-Driven Discovery for Obesity TreatmentNASDAQ:HOTHHoth Therapeutics Inc
19/03/202412:21PR Newswire (US)Hoth Therapeutics Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZNASDAQ:HOTHHoth Therapeutics Inc
29/02/202413:38PR Newswire (US)Hoth Therapeutics Retains Venable LLP to Expand Its Patent PortfolioNASDAQ:HOTHHoth Therapeutics Inc
26/02/202413:11PR Newswire (US)Hoth Therapeutics Engages Altasciences to Perform Key Study for HT-KIT Cancer Fighting TherapeuticNASDAQ:HOTHHoth Therapeutics Inc
13/02/202416:45PR Newswire (US)Hoth Therapeutics to Attend BIO CEO and Investor Conference, February 26-27, 2024NASDAQ:HOTHHoth Therapeutics Inc
18/01/202413:20PR Newswire (US)Hoth Therapeutics Announces it Received FDA Approval to Expand HT-001 Clinical Trial to Treat Severely Ill PatientsNASDAQ:HOTHHoth Therapeutics Inc
09/01/202420:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:HOTHHoth Therapeutics Inc
08/01/202422:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HOTHHoth Therapeutics Inc
08/01/202422:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HOTHHoth Therapeutics Inc
08/01/202422:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HOTHHoth Therapeutics Inc
08/01/202422:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HOTHHoth Therapeutics Inc
27/12/202313:21PR Newswire (US)Hoth Therapeutics Announces Expansion of FDA Cleared First-In-Human Clinical Trial For Cancer Patients of HT-001 at University of MiamiNASDAQ:HOTHHoth Therapeutics Inc
05/12/202313:33PR Newswire (US)Hoth Therapeutics Announces it Has Successfully Completed Manufacturing of its Cancer fighting HT-KIT for IND-Enabling StudiesNASDAQ:HOTHHoth Therapeutics Inc
14/11/202313:37PR Newswire (US)Hoth Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Development of Hoth's Cancer Fighting HT-KITNASDAQ:HOTHHoth Therapeutics Inc
13/11/202321:16Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:HOTHHoth Therapeutics Inc
10/11/202313:00PR Newswire (US)Hoth Therapeutics to Present at NobleCon's 19th Annual Emerging Growth Investor Conference, December 3-5, 2023NASDAQ:HOTHHoth Therapeutics Inc
05/10/202315:03PR Newswire (US)Hoth Therapeutics Announces Merveille.ai Artificial intelligence Initiative for Drug DiscoveryNASDAQ:HOTHHoth Therapeutics Inc
05/10/202313:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:HOTHHoth Therapeutics Inc
02/10/202313:33PR Newswire (US)FDA Grants Hoth Therapeutics Pre-IND Meeting for HT-KIT, Treatment for Cancer PatientsNASDAQ:HOTHHoth Therapeutics Inc
15/09/202321:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:HOTHHoth Therapeutics Inc
15/09/202319:38PR Newswire (US)Hoth Therapeutics Announces Closing of $2.89 Million Registered Direct Offering Priced At-The-Market under Nasdaq RulesNASDAQ:HOTHHoth Therapeutics Inc
14/09/202322:24Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:HOTHHoth Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:HOTH

Your Recent History

LSE
POS
Plexus
LSE
PHNX
Phoenix
LSE
QBT
Quantum Blockchain Techn...
LSE
PANR
Pantheon Resources
LSE
AAZ
Anglo Asian Mining
LSE
LLOY
Lloyds Banking
LSE
SEE
Seeing Machines
LSE
EME
Empyrean Energy
LSE
VAST
Vast Resources
LSE
GKP
Gulf Keystone Petroleum
LSE
I3E
I3 Energy
LSE
GMET
Golden Metal Resources
LSE
SYME
Supply@me Capital
LSE
AAU
Ariana Resources
LSE
VLX
Volex
LSE
TERN
Tern
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved